PatientsVille.com Logo

OROPHARYNGEAL PAIN and Pradaxa

PatientsVille

OROPHARYNGEAL PAIN Symptoms and Causes

Throat cancer is a type of head and neck cancer. Throat cancer has different names, depending on which part of the throat is affected. The different parts of your throat are called the oropharynx, the hypopharynx, the nasopharynx, and the larynx, or voice box.

The main risk factors for throat cancer are using tobacco heavy drinking. Certain types of throat cancer also have other risk factors. For example, having HPV is a risk factor for oropharyngeal cancer.

Symptoms of throat cancer may include

  • A sore throat that does not go away
  • A lump in the neck
  • Pain or ringing in the ears
  • Trouble swallowing
  • Ear pain

To diagnose throat cancers, doctors may do a physical exam and history, imaging tests, and a biopsy. You may also need other tests, depending on the type of cancer. Treatments include surgery, radiation therapy, and chemotherapy. Treatment for some types of throat cancer may also include targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells.

NIH: National Cancer Institute

Check out the latest treatments for OROPHARYNGEAL PAIN

OROPHARYNGEAL PAIN treatment research studies

Pradaxa clinical trials, surveys and public health registries


Find Drug Side Effect reports



Pradaxa Side Effects

Gastrointestinal Haemorrhage (2049)
Anaemia (785)
Cerebrovascular Accident (760)
Haemorrhage (724)
Fall (618)
Rectal Haemorrhage (581)
Renal Failure Acute (471)
Dizziness (465)
Dyspepsia (439)
Haemorrhagic Anaemia (428)
Coagulopathy (420)
Dyspnoea (414)
Ischaemic Stroke (406)
Contusion (388)
Epistaxis (381)
Nausea (379)
Melaena (366)
Haemoglobin Decreased (363)
Asthenia (351)
Death (342)
Cerebral Haemorrhage (303)
Lower Gastrointestinal Haemorrhage (292)
Diarrhoea (283)
Haematuria (281)
Atrial Fibrillation (279)
Upper Gastrointestinal Haemorrhage (267)
Headache (267)
Pulmonary Embolism (264)
Haematochezia (264)
Deep Vein Thrombosis (258)
Myocardial Infarction (252)
Fatigue (246)
International Normalised Ratio Increased (241)
Haemorrhage Intracranial (239)
Renal Failure (235)
Arthralgia (230)
Transient Ischaemic Attack (218)
Abdominal Pain Upper (213)
Cerebral Infarction (207)
Chest Pain (207)
Abdominal Discomfort (198)
Pneumonia (192)
Vomiting (190)
Haematoma (181)
Abdominal Pain (178)
Subdural Haematoma (170)
Pain In Extremity (164)
Oedema Peripheral (164)
Renal Impairment (160)
Haemoptysis (156)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

I'm over 80, very active working 6 days a week, walking briskly about 6 x 10 minutes daily, with Verapamil and 100 mg aspirin (also diabetic and asthmatic - completely under control). Had a biological aortic valve replacement, very s

While taking Pradaxa I had severe knife feeling pain in left eye. I have been off 2 days and it is better. I will check with eye docotr this week and see if it is eye or meds.

I have been Pradaxa for almost a month had severe outbreak of hives on my feet and my legs up to my knees. I also having swelling of legs and feet along with fatigue in joints and body limbs. Doctor changed my Med. but the side effects is still o

3 MONTHS TAKING PRADAXA WITH NO SIDE EFFECTS

Since taking Prodaxa I am experiencing shortness of breath...

I been taking pradaxa for 14 days and have a severe rash, doctor to start warfarin again.

my husband has been on pradaxa for a month he cannot eat has lost 26 lbs gets chills and then feels hot, vomiting.

Want to know if it could cause my extreme tiredness.

<b>Describe Your Pradaxa Experience Here:</b>tired and fluid retention

<b>Describe Your Pradaxa Experience Here:</b>itching that last five minutes and goes away i have swelled knee pain also arthritis

I took Beano (only one pill) last week and 2 hours later I ended up with a terrible stomach pain.I did not connect the dots, I suspected that it was caused by certain ingredients in the food I was eating. Itwas a very unique pain

Yesterday, after taking Sam-e with Glucosamine. I got a pain between my shoulder blade, jaw pain, dizziness, sweating. felt like a heart attack. I did not go to the hospital because of the money needed. No ins

<b><span style='font-weight: normal;'><b>After 6 weeks of oral lamisil I experienced</b>eczema, muscle weakness, asthma, bloody bowels, lower abdominal pain, dizziness, extreme f

63 yo man received Zostavax injection in the left upper arm 12/13/11. Developed painful blister on the right shoulder and pain at the right lower ribs 12/10/11.

After using Clobetasol for a two week cycle, my doctor suggested I use it one day during the week, applying it twice that day. Since that time, I have experinced severe chest pain. I recently saw my doctor for heart attack symptoms before I reali

Arthritis Treatment Safe, Natural Cure for Adults. Synflex Liquid Glucosamine, Rheumatoid Arthritis Joint Pain Relief Remedy, Diet Supplements. Synflex, Glucosamine for Dogs. Free Shipping! &lt;a href='http://www.healthyjointcare.com/'&g

My father is 68 and retired, he is also diabetic. He suffers from severe joints, hip and back pain. He has been using panadol extra strength but finds it takes too long to act. He is also allergic to aspirin and was hospitalized with a ruptured u

While taking Pradaxa I had severe knife feeling pain in left eye. I have been off 2 days and it is better. I will check with eye docotr this week and see if it is eye or meds.

Yes I am Aspavor 20mg and also have a back pain were I am constantly taking pain killers. I actually thought that I did some thing wrong by lifting but just from sitting or turning my body it will return it starts to effect my job off shore and h

i feel nick pain & headache i am ussed 9th month

OROPHARYNGEAL PAIN Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Management of Myocardial Injury After Noncardiac Surgery Trial
Condition: Myocardial Injury After Noncardiac Surgery (MINS)
Interventions: Drug: Dabigatran;   Drug: Placebo (for Dabigatran);   Drug: Omeprazole;   Drug: Placebo (for Omeprazole)
Outcome Measures: Major vascular complication (for Dabigatran);   Major upper gastrointestinal complication (for Omeprazole);   Individual secondary outcomes for Dabigatran;   Upper gastrointestinal complication for Omeprazole;   Major vascular complication for Omeprazole;   Individual secondary outcomes for Omeprazole;   Safety outcomes for Dabigatran;   Safety outcomes for Omeprazole
2 Recruiting Strategy of Continued Versus Interrupted Dabigatran at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events
Condition: Hematoma
Intervention: Drug: Dabigatran
Outcome Measures: Clinically significant hematoma;   Composite of major peri-operative bleeding events and thrombo-embolic events
3 Recruiting Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively
Condition: Primary Disease
Interventions: Drug: Dabigatran;   Drug: Warfarin
Outcome Measures: Embolic Events;   Bleeding
4 Recruiting SPARK: Safety Study of Pradaxa in Atrial Fibrillation Patients by Regulatory Requirement of Korea
Condition: Atrial Fibrillation
Intervention: Drug: Pradaxa (Dabigatran etexilate mesilate)
Outcome Measures: Occurrence of adverse events;   Incidence rate of stroke;   Incidence rate of systemic embolism
5 Recruiting Drug Interaction Study Between Bosutinib And Dabigatran
Condition: Healthy
Interventions: Drug: Dabigatran;   Drug: Bosutinib
Outcome Measures: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast);   Maximum Observed Plasma Concentration (Cmax);   Time to Reach Maximum Observed Plasma Concentration (Tmax);   Plasma Decay Half-Life (t1/2);   Apparent Oral Clearance (CL/F);   Apparent Volume of Distribution (Vz/F)
6 Recruiting Dabigatran's Effect on Changes in Atrial Fibrosis in Patients With Atrial Fibrillation
Condition: Atrial Fibrillation
Intervention: Drug: Dabigatran etexilate (Pradaxa)
Outcome Measure: Percentage of fibrosis
7 Recruiting Dabigatran Treatment Following Transient Ischemic Attack and Minor Stroke
Conditions: Transient Ischemic Attack;   Minor Ischemic Stroke
Intervention: Drug: Dabigatran 110/150 mg BID
Outcome Measure: Symptomatic Hemorrhagic Transformation
8 Recruiting Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism
Conditions: Atrial Fibrillation;   Atrial Flutter
Intervention: Drug: dabigatran etexilate mesylate
Outcome Measures: Frequency of major bleeding complications and thrombo-embolic events in patients administered dabigatran following RF ablation.;   Dabigatran serum drug levels in patients experiencing a major bleeding or thrombo-embolic event.;   Frequency of minor bleeding events
9 Recruiting Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
Condition: Atrial Fibrillation
Intervention: Drug: Pradaxa, dabigatran etexilate
Outcome Measures: Pre-dose concentration of the analyte in plasma at steady state immediately before administration of the next dose;   Concentration of analyte in plasma at steady state at 2 hours after administration of the last dose
10 Recruiting Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)
Condition: Venous Thromboembolism
Interventions: Drug: dabigatran etexilate;   Drug: standard of care
Outcome Measures: First component of the co-primary endpoint: A combined efficacy endpoint of complete thrombus resolution plus freedom from recurrent VTE plus freedom from mortality related to VTE;   Second component of the co-primary endpoint: Freedom from major bleeding events (a safety endpoint);   Pharmacokinetic assessments (plasma concentrations of total dabigatran) 3 days after start of treatment (after at least six consecutive dabigatran doses) and after 3 days following any dabigatran dose adjustment;   Frequency of dose adjustments;   Frequency of switch of type of anti-coagulation therapy (including dabigatran to SOC) and a switch from an intended standard of care treatment to another;   Freedom from thrombus progression at baseline and at days 21 and 84 after randomisation;   Assessment of the acceptability of an age-appropriate formulation at end of therapy;   Freedom from recurrence of VTE at 6, 9 and 12 months;   Freedom from occurrence of post-thrombotic syndrome at 6, 9 and 12 months;   All bleeding events;   All-cause mortality;   All components of the primary efficacy endpoints;   Pharmacodynamic assessments (aPTT, ecarin clotting time (ECT) and dTT) 3 days after start of treatment (after at least six consecutive dabigatran doses) and after 3 days following any dabigatran dose adjustment;   Frequency of temporary discontinuation from therapy;   Frequency of permanent discontinuation from therapy;   Number of laboratory monitoring requirements for dose adjustment during the treatment phase
11 Recruiting Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
Condition: Venous Thromboembolism
Intervention: Drug: dabigatran etexilate
Outcome Measures: Plasma concentrations of total dabigatran;   Plasma concentrations of free dabigatran;   Plasma concentrations of BIBR 1048 BS (Base);   Plasma concentrations of BIBR 951 BS;   Plasma concentrations of BIBR 1087 SE (Acid);   Activated prothrombin time (aPTT);   Ecarin clotting time (ECT);   Factor IIa inhibition;   Incidence of all bleeding events;   Incidence of all adverse events;   Global assessment of tolerability will be summarized across all patients in the treated set;   Patient assessment of taste will be summarized across all patients in the treated set;   Changes in laboratory and clinical parameters
12 Recruiting Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation
Conditions: Coronary Heart Disease;   Atrial Fibrillation;   Acute Coronary Syndrome;   Atherosclerosis
Interventions: Drug: Dabigatran;   Drug: Phenprocoumon
Outcome Measures: ADP induced platelet aggregation;   Platelet function tests;   Coagulation parameters
13 Not yet recruiting Validation of a Novel Dabigatran Based Peri-Operative Bridging Anticoagulation Protocol for Patients on Chronic Warfarin Therapy
Condition: Venous Thrombembolic Events.
Intervention: Drug: Dabigatran.
Outcome Measure: Validation of a novel Dabigatran Based Peri-Operative Bridging Anticoagulation Protocol for Patients on Chronic Warfarin Therapy
14 Not yet recruiting Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa
Conditions: Atrial Fibrillation;   Hemorrhage
Interventions: Drug: Dabigatran 75 mg;   Drug: Dabigatran 150 mg
Outcome Measures: Number of patients with index event safety outcomes (ongoing/resolved/deceased);   Number of patients receiving different types of interventions to stop the index events;   Frequencies of bleeding types and anatomic locations of the index event
15 Recruiting Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of Age
Condition: Venous Thromboembolism
Intervention: Drug: dabigatran etexilate
Outcome Measures: Ecarin clotting time (ECT);   Factor IIa inhibition;   Incidence of all bleeding events;   Incidence of all adverse events;   Plasma concentrations of total dabigatran;   Plasma concentrations of free dabigatran;   Plasma concentrations of BIBR 1048 BS (Base);   Plasma concentrations of BIBR 951 BS;   Plasma concentrations of BIBR 1087 SE (Acid);   Activated prothrombin time (aPTT);   Global assessment of tolerability will be summarized across all patients in the treated set;   Patient assessment of taste will be summarized across all patients in the treated set;   Changes in laboratory and clinical parameters
16 Recruiting Safety Study of Dabigatran in CADASIL
Condition: CADASIL
Interventions: Drug: Dabigatran;   Drug: Antiplatelets
Outcome Measures: Number of microbleeds on MRI;   Major bleeding
17 Not yet recruiting Cognitive Impairment Related to Atrial Fibrillation Prevention Trial
Condition: Atrial Fibrillation
Interventions: Drug: Warfarin;   Drug: Dabigatran
Outcome Measures: Cognitive impairment;   Number of Participants with less important alteration in coagulation test as a Measure of Safety
18 Recruiting Reversal of Dabigatran Anticoagulant Effect With Idarucizumab
Condition: Hemorrhage
Intervention: Drug: idarucizumab
Outcome Measures: Reversal of anticoagulant effect of dabigatran;   Reversal of Activated Partial Thromboplastin Time (aPTT);   Reversal of Thrombin Time (TT);   Duration of reversal;   Occurrence of major bleeding post-surgery (for Group B only);   Time to cessation of bleeding (for Group A only);   Minimum unbound sum (free) dabigatran;   Reversal of diluted Thrombin Time (dTT) or Ecarin Clotting Time (ECT) after the first infusion and before the start of the second
19 Recruiting Pharmacogenomic Study on PKD/PKC of Dabigatran Etexilate and Rivaroxaban
Condition: Healthy Volunteers
Interventions: Drug: D->R->C+R;   Drug: D->R->C+D;   Drug: R->D->C+D;   Drug: R->D->C+R
Outcome Measures: AUC of plasma concentrations of the drugs;   PKD of the drugs
20 Recruiting Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery
Conditions: Arthroplasty, Replacement;   Thromboembolism
Intervention:
Outcome Measures: Safety: Major bleeding events. Efficacy: composite of all death and documented symptomatic VTE (i.e documented symptomatic DVT and documented symptomatic nonfatal pulmonary embolism).;   Major extra surgical site bleedings,volume of wound drainage, documented symptomatic proximal DVT, documented symptomatic distal DVT, documented symptomatic nonfatal pulmonary embolism and all-cause mortality